The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...

A new compound called CMX410 may change the fight against tuberculosis. It targets a weak point in the bacteria’s defenses, even in drug-resistant forms of the disease. Created using a cutting-edge ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat ...

Increased availability of testing and antiretrovirals has led to global progress in preventing and managing infectious diseases like HIV, tuberculosis (TB), malaria and hepatitis in the last quarter ...

Daewoong Pharmaceutical is participating as a key research partner in a government-led project to establish an artificial ...

Massimo Radaelli, PhD, is a European pharmaceutical industry leader and entrepreneur who has devoted more than 30 years to the innovation of therapies to treat rare diseases. He is President and CEO ...

What the CBO calls an increase in "federal spending" is, in reality, an investment in restoring hope and innovation for our most vulnerable patients suffering from devastating rare diseases. The ...

Your editorial on “Why Vinay Prasad Had to Go at FDA” should be a wake-up call for anyone who cares whether federal bureaucrats get to decide if promising new medicines are available to desperately ...

Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and other devastating autoimmune diseases — by reprogramming patients’ out-of-whack immune ...

Some of the most ambitious cancer science is happening in a disease few outside of oncology can name, and it’s revealing a future where cancer is no longer a death sentence. Multiple myeloma (MM) is a ...